文献速递前列腺癌

根治性前列腺切除术与观察治疗临床局限性前列腺癌:PIVOT试验长期随访

Radical Prostatectomy or Observation for Clinically Localized Prostate Cancer: Extended Follow-up of the Prostate Cancer Intervention Versus Observation Trial (PIVOT).
PubMed 文献 · Eur Urol · 2020-02-21

PIVOT随机试验长期随访(中位18.6年)显示,根治性前列腺切除术与观察相比,全因死亡率风险比0.84(95%CI 0.70-1.00,P=0.044),绝对风险降低5.7个百分点(95%CI -0.89至12%),平均获得1个生命年。绝对效应在低危患者中更小,中危患者更大,高危患者未见明显获益。

要点

  • 手术与观察相比全因死亡风险比0.84,绝对风险降低5.7个百分点,平均获得1个生命年。
  • 低危患者绝对效应更小,中危患者更大,高危患者未见明显获益。
  • 结果未按多重比较校正,且仅评估全因死亡率。

核心结论

  • 手术与观察相比,全因死亡率有小幅长期降低,并增加获得的生命年。
  • 绝对效应在低危患者中更小,中危患者更大,高危患者未见明显获益。

研究设计与样本

  • 随机对照试验长期随访,纳入731例≤75岁、PSA<50ng/ml、预期寿命≥10年且适合手术的局限性前列腺癌男性。
  • 干预为根治性前列腺切除术对比观察,主要结局为全因死亡率,采用意向性分析。

主要发现

  • 中位随访18.6年(四分位距16.6-20.0),共515例死亡;手术组246/346(68%),观察组269/367(73%)。
  • 全因死亡风险比0.84(95%CI 0.70-1.00;P=0.044),绝对风险降低5.7个百分点(95%CI -0.89至12%),相对风险0.92(95%CI 0.84-1.01)。
  • 手术组限制性平均生存13.6年(95%CI 12.9-14.3),观察组12.6年(95%CI 11.8-13.3),平均获得1个生命年。
  • 亚组分析未显示显著异质性,但<65岁、白人、健康状况更好、合并症更少、阳性穿刺针≥34%及中危患者中手术获益差异更大。

临床怎么用

  • 对于临床局限性前列腺癌,手术可带来小幅长期全因死亡获益,决策时应结合风险分层。
  • 低危患者绝对获益小,中危患者获益相对更大,高危患者未见明显获益,需个体化权衡。

局限性

  • 结果未针对多重比较进行校正。
  • 仅评估全因死亡率,未评估其他结局。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Very long-term mortality in men with early prostate cancer treated with surgery versus observation is uncertain. OBJECTIVE: To determine long-term effects of surgery versus observation on all-cause mortality for men with early prostate cancer. DESIGN, SETTING, AND PARTICIPANTS: This study evaluated long-term follow-up of a randomized trial conducted at the US Department of Veterans Affairs and National Cancer Institute sites. The participants were men (n=731) ≤75yr of age with localized prostate cancer, prostate-specific antigen (PSA) <50ng/ml, life expectancy ≥10yr, and medically fit for surgery. INTERVENTION: Radical prostatectomy versus observation. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: All-cause mortality was assessed in the entire cohort and patient and tumor subgroups. Intention-to-treat analysis was conducted using Kaplan-Meier methods with log-rank tests and Cox proportional hazard models; cumulative mortality incidence, between-group differences, and relative risks were also assessed at predefined time periods. RESULTS AND LIMITATIONS: During 22.1yr (median follow-up for survivors=18.6yr; interquartile range: 16.6-20.0), 515 men died; 246 of 346 men (68%) were assigned to surgery versus 269 of 367 (73%) assigned to observation (hazard ratio 0.84 [95% confidence interval {CI}: 0.70-1.00]; p= 0.044 [absolute risk reduction = 5.7 percentage points, 95% CI: -0.89 to 12%]; relative risk: 0.92 [95% CI: 0.84-1.01]). The restricted mean survival in the surgical group was 13.6 yr (95% CI: 12.9-14.3) versus 12.6 yr (95% CI: 11.8-13.3) in the observation group; a mean of 1 life-year was gained with surgery. Results did not significantly vary by patient or tumor characteristics, although differences were larger favoring surgery among men aged <65 yr, of white race, and having better health status, fewer comorbidities, ≥34% positive prostate biopsy cores, and intermediate-risk disease. Results were not adjusted for multiple comparisons, and we could not assess outcomes other than all-cause mortality. CONCLUSIONS: Surgery was associated with small very long-term reductions in all-cause mortality and increases in years of life gained. Absolute effects did not vary markedly by patient characteristics. Absolute effects and mean survival were much smaller in men with low-risk disease, but were greater in men with intermediate-risk disease although not in men with high-risk disease. PATIENT SUMMARY: In this randomized study, we evaluated death from any cause in men with early prostate cancer treated with either surgery or observation. Overall, surgery may provide small very long-term reductions in death from any cause and increases in years of life gained. Absolute effects were much smaller in men with low-risk disease, but were greater in men with intermediate-risk disease although not in men with high-risk disease. Strategies are needed to identify men needing and benefitting from surgery while reducing ineffective treatment and overtreatment.

来源:Eur Urol,查看原文。版权归原作者所有。

引用

  1. Wilt TJ, Vo TN, Langsetmo L, et al. Radical Prostatectomy or Observation for Clinically Localized Prostate Cancer: Extended Follow-up of the Prostate Cancer Intervention Versus Observation Trial (PIVOT). Eur Urol. 2020. PMID: 32089359. doi:10.1016/j.eururo.2020.02.009

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。